Inventiva announce the publication in a peer reviewed publication of data on IVA337 in…

Confirmation of the therapeutic potential of IVA337 for the treatment of patients with NASH

Download the free guide
Boost your gains

Aix (France), June 20, 2017 – Inventiva (Euronext Paris — FR0013233012 – IVA), a biopharmaceutical company specializing in the development of innovative treatments, including fibrosis, today announced the publication, in a peer-reviewed journal, data on the effects of its drug candidate IVA337, an agonist of pan-PPAR currently in phase IIb clinical development in Non-Alcoholic Steatohepatitis (NASH), in different preclinical models of NASH. The article The New-Generation Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis has been published in the edition of June 19, 2017 of the journal Hepatology Communications. Hepatology Communications is a scientific journal only available on-line, peer-reviewed, that allows the rapid diffusion of basic research, translational and clinical high-quality in the field of hepatology. It is supported by the prestigious network of journals and learned societies Wiley.

The authors of the article are prominent scholars of NASH, including Professor Isabelle Leclerc of the University of Louvain (Belgium), Professor Derek Mann from Newcastle University (Uk) and Professor Sven Francque University Hospital of Antwerp (Belgium), as well as scientists at Inventiva.

“We are very pleased to announce the publication of our data on IVA337 in this peer reviewed journal. These studies on several relevant animal models demonstrate that the molecule improves metabolic parameters as well as histopathological characteristics of NASH such as steatosis, ballooning, inflammation and fibrosis, ” explains Dr. Pierre Broqua, Chief scientific officer and Co-founder of Inventiva. “In the light of these results and of its good safety profile, different from that of agonists of PPAR that have previously been developed, IVA337 would be a promising candidate for the treatment of NASH. This is why we are currently in the process of recruiting patients with NASH in a Phase IIb clinical study evaluating IVA337.”

About Inventiva :

Inventiva is a biopharmaceutical company specializing in the development of drugs acting on nuclear receptors, transcription factors and epigenetic modulation. Inventiva opens new avenues for innovative therapies in the field of fibrotic diseases, oncology, and orphan diseases for which the medical need is important.
Its flagship product, IVA337, is a drug candidate that has a unique mechanism of action through activation of the PPAR (receptor activated peroxisome proliferator -) alpha, gamma and delta, which play a fundamental role in the control of the fibrotic process. Its anti-fibrotic in particular allows you to target two indications to strong medical need : the NASH, a severe pathology of the liver in strong growth and which already affects the United States more than 30 million people, and the systemic scleroderma, a disease in which the mortality rate is very high and without any treatment approved to date.
Inventiva is developing in parallel a second clinical program with IVA336, a drug candidate for the treatment of three forms of mucopolysaccharidoses (MPS I, or syndrome, Hurler-Scheie, MPS II, or syndrome, Hunter and MPS VI or Maroteaux-Lamy syndrome), as well as a portfolio of pre-clinical projects in the field of oncology.
Inventiva is surrounded by well-known partners in the area of the research, such as the Curie Institute. Two strategic partnerships, one of which at the clinical stage, have also been put in place with AbbVie and Boehringer Ingelheim, which include, in particular, for the payment to Inventiva of payments based on the achievement of objectives pre-clinical, clinical, regulatory and commercial, as well as royalties on sales of products developed in the framework of these partnerships.
Inventiva employs more than 100 highly qualified people and has R&D facilities of cutting edge purchased at the international pharmaceutical company Abbott, regrouping, near Dijon, a chemical library of more than 240 000 molecules and platforms in biology, chemistry, ADME, and pharmacology.

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply